Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter ...

Novo Nordisk reduced its starter dose prices through telehealth platforms to encourage patients to wean themselves off compounded copycats.

Houston Chronicle reporter Julian Gill discusses his recent investigation on Eli Lilly targeting a Houston-based pharmacy ...

The pharma companies selling the branded drugs, Novo Nordisk and Eli Lilly, have started offering ... Pharma companies have been locked in legal battles against compounders, arguing the copies ...

It's plainly apparent that Novo Nordisk has had May 22 circled its calendar since February, when the FDA began the countdown ...

President Donald Trump is under pressure to decide how widely available anti-obesity drugs should be and whether Medicare should cover them.

Ozempic made headlines. Now its maker faces stock crashes, CEO fallout, and fierce rivalry from Eli Lilly. Discover the trade behind the drama.

Attorney James Gourley details the many legal issues surrounding the GLP-1 drug market and offers advice to companies on how ...

Pharma giant Eli Lilly may plant a $5.9 billion manufacturing facility in Houston’s Generation Park, bringing serious biotech ...